-The Times of India NEW DELHI: India's march towards being an economically stable nation is threatened not just by global financial issues. Poor health indicators pose an equally big threat. The Harvard School of Public Health has, in a study on economic losses due to non-communicable diseases (NCDs), estimated that the economic burden of these ailments for India will be close to $6.2 trillion for the period 2012-30, a figure that is...
More »SEARCH RESULT
Total Matching Records found : 76
Epidemic of Vitamin D shortage puts Indians at high blood pressure risk -Malathy Iyer
-The Times of India MUMBAI: Runny noses and stomach flu aren't the only ills associated with overcast skies. The absence of sunlight hits production of Vitamin D in the body, adversely affecting blood pressure. A recent study in London by an Indian-born researcher has proved beyond doubt that the lower the vitamin level, the higher the BP. Vitamin D is synthesized when the sun's ultraviolet rays fall on the skin. But the...
More »Slow Poison-A Srinivas
-The Hindu Business Line Arsenic and fluoride contaminated water has condemned millions to live wasted lives in West Bengal, Andhra Pradesh and Karnataka. Business Line visited several villages in the affected regions for this special report by A. Srinivas. Sixty-nine-year-old Renubala Ari of Deganga village in West Bengal's North 24 Parganas district is counting her last days. But it is not her death that worries her. Blind in both eyes and with painful...
More »More battles in store-Aarti Dhar
-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...
More »Novartis order may force pharma MNCs to change
-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...
More »
